Lilly’s Gene-Editing Shot Cuts Bad Cholesterol Up to 62 Percent
Eli Lilly’s gene-editing therapy VERVE-102 shows promise by reducing bad cholesterol up to 62 percent in early trials, potentially transforming
·
3 min read